FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following ...

Annual treatments worth £6,000: Prescription hydrofacial, £1,000; Morpheus8, £1,300; Profhilo, £1,200; Botox, £760; Belotero ...

There’s no one-size-fits-all ‘mommy makeover’—here’s what it’s actually like to get different versions of this popular ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Ozempic, approved for Type 2 diabetes, has gained fame for its weight-loss properties, especially among celebrities. Despite its rising popularity, experts warn of potential side effects like ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America: Ozempic.